Novocure Ltd (NASDAQ:NVCR) COO Michael J. Ambrogi sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 9th. The shares were sold at an average price of $40.00, for a total transaction of $4,000,000.00. Following the completion of the transaction, the chief operating officer now directly owns 221,558 shares in the company, valued at $8,862,320. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ NVCR traded up $1.25 during midday trading on Friday, reaching $43.25. 876,930 shares of the stock were exchanged, compared to its average volume of 791,356. The stock has a market cap of $3.76 billion, a price-to-earnings ratio of -61.79 and a beta of 2.86. Novocure Ltd has a 12 month low of $19.06 and a 12 month high of $53.70. The company has a quick ratio of 5.72, a current ratio of 6.17 and a debt-to-equity ratio of 1.30.

Novocure (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, October 25th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The company had revenue of $64.76 million for the quarter, compared to analysts’ expectations of $65.61 million. Novocure had a negative net margin of 25.37% and a negative return on equity of 52.72%. On average, research analysts anticipate that Novocure Ltd will post -0.68 EPS for the current fiscal year.

A number of equities analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Novocure from a “buy” rating to a “hold” rating in a research report on Tuesday, October 30th. ValuEngine raised shares of Novocure from a “buy” rating to a “strong-buy” rating in a research report on Thursday. BidaskClub raised shares of Novocure from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Mizuho reissued a “buy” rating and set a $51.00 price target on shares of Novocure in a research report on Thursday, December 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $48.00.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its position in Novocure by 37.9% in the 3rd quarter. FMR LLC now owns 10,845,246 shares of the medical equipment provider’s stock valued at $568,292,000 after acquiring an additional 2,983,125 shares in the last quarter. Vanguard Group Inc. lifted its position in Novocure by 9.6% in the 3rd quarter. Vanguard Group Inc. now owns 5,424,908 shares of the medical equipment provider’s stock valued at $284,265,000 after acquiring an additional 476,635 shares in the last quarter. Vanguard Group Inc lifted its position in Novocure by 9.6% in the 3rd quarter. Vanguard Group Inc now owns 5,424,908 shares of the medical equipment provider’s stock valued at $284,265,000 after acquiring an additional 476,635 shares in the last quarter. BlackRock Inc. lifted its position in Novocure by 2.8% in the 3rd quarter. BlackRock Inc. now owns 4,749,934 shares of the medical equipment provider’s stock valued at $248,897,000 after acquiring an additional 129,388 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its position in Novocure by 14.0% in the 3rd quarter. Baillie Gifford & Co. now owns 3,527,100 shares of the medical equipment provider’s stock valued at $184,821,000 after acquiring an additional 433,705 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Novocure Ltd (NVCR) COO Sells $4,000,000.00 in Stock” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2019/01/11/novocure-ltd-nvcr-coo-sells-4000000-00-in-stock.html.

About Novocure

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

See Also: No Load Funds

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.